[go: up one dir, main page]

AU2001280471A1 - Novel secreted proteins and their uses - Google Patents

Novel secreted proteins and their uses

Info

Publication number
AU2001280471A1
AU2001280471A1 AU2001280471A AU8047101A AU2001280471A1 AU 2001280471 A1 AU2001280471 A1 AU 2001280471A1 AU 2001280471 A AU2001280471 A AU 2001280471A AU 8047101 A AU8047101 A AU 8047101A AU 2001280471 A1 AU2001280471 A1 AU 2001280471A1
Authority
AU
Australia
Prior art keywords
secreted proteins
novel secreted
novel
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280471A
Inventor
Brian Taylor Edmonds
Radmila Micanovic
Weijia Ou
Eric Wen Su
Sheng-Hung Rainbow Tschang
He Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001280471A1 publication Critical patent/AU2001280471A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001280471A 2000-08-11 2001-07-30 Novel secreted proteins and their uses Abandoned AU2001280471A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22464200P 2000-08-11 2000-08-11
US60/224,642 2000-08-11
US24177900P 2000-10-19 2000-10-19
US60/241,779 2000-10-19
PCT/US2001/021124 WO2002014358A2 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Publications (1)

Publication Number Publication Date
AU2001280471A1 true AU2001280471A1 (en) 2002-02-25

Family

ID=26918895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280471A Abandoned AU2001280471A1 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Country Status (3)

Country Link
EP (1) EP1309614A2 (en)
AU (1) AU2001280471A1 (en)
WO (1) WO2002014358A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255771A4 (en) * 2000-02-14 2004-09-29 Smithkline Beecham Corp Novel compounds
WO2002040654A2 (en) 2000-11-14 2002-05-23 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100136028A1 (en) 2006-11-07 2010-06-03 Sparrow Carl P Antagonists of pcsk9
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CA2680832A1 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
LT2530091T (en) 2010-01-29 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
AR087715A1 (en) 2011-09-16 2014-04-09 Lilly Co Eli ANTI PCSK9 ANTIBODIES AND USES OF THE SAME
ME02928B (en) 2012-02-24 2018-04-20 Abbvie Stemcentrx Llc DLL3 MODULATORS AND USE METHOD
AR091462A1 (en) 2012-06-15 2015-02-04 Genentech Inc ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE
CN105164159A (en) 2013-02-22 2015-12-16 施特姆森特克斯股份有限公司 Novel antibody conjugates and uses thereof
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
BR112016018891A2 (en) 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anti-dll3 antibodies and drug conjugates for use in melanoma
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
IL267500B2 (en) 2016-12-23 2025-07-01 Harvard College Gene editing of pcsk9 and related methods, compositions, and uses thereof
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN115397866A (en) 2020-03-31 2022-11-25 中外制药株式会社 DLL 3-targeted multispecific antigen-binding molecules and uses thereof
GB2625902B (en) 2020-04-09 2025-02-12 Verve Therapeutics Inc Base editing of pcsk9 and methods of using same for treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916751A (en) * 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
US6635480B1 (en) * 1997-07-31 2003-10-21 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
AU9108698A (en) * 1997-08-21 1999-03-08 Human Genome Sciences, Inc. Human nodal and lefty homologues
US6027917A (en) * 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
EP1436013A2 (en) * 1999-04-29 2004-07-14 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue

Also Published As

Publication number Publication date
WO2002014358A3 (en) 2003-03-13
WO2002014358A2 (en) 2002-02-21
EP1309614A2 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
AU2001280471A1 (en) Novel secreted proteins and their uses
AU7602400A (en) Secreted proteins and uses thereof
AU2001271683A1 (en) Novel secreted proteins
AU2001237958A1 (en) 22 human secreted proteins
AU2002233994A1 (en) Secreted proteins
AU2001270045A1 (en) Secreted proteins
AU2001227833A1 (en) 71 human secreted proteins
AU2002232596A1 (en) Secreted human proteins
AU6394400A (en) Secreted proteins and uses thereof
AU2001255320A1 (en) Secreted proteins
AU2001237957A1 (en) 17 human secreted proteins
AU2001245308A1 (en) 207 human secreted proteins
AU2396600A (en) Secreted proteins and uses thereof
AU2002211220A1 (en) Secreted proteins and their uses
AU5750200A (en) Secreted proteins and uses thereof
AU2001290551A1 (en) Secreted proteins and their uses
AU2002236440A1 (en) Novel secreted proteins and their uses
AU2001294719A1 (en) Secreted human proteins
AU3382800A (en) Secreted proteins and uses thereof
AU1190801A (en) Secreted proteins and uses thereof
WO2000069885A8 (en) Secreted proteins and uses thereof
AU2001229366A1 (en) Secreted proteins
AU2001229507A1 (en) 21 human secreted proteins
AU2001283327A1 (en) 8 human secreted proteins
AU2001255668A1 (en) 29 human secreted proteins